Systemic, local, and sclerotherapy drugs: What do we know about drug prescribing in vascular anomalies?. Issue 12 (1st October 2021)

• Record Type: Journal Article
• Authors: Marcoux, Simon; Théorêt, Yves; Dubois, Josée; Essouri, Sandrine; Pincivy, Alix; Coulombe, Jérôme; McCuaig, Catherine; Powell, Julie; Soulez, Gilles; Kleiber, Niina
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 12(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-01
• Subjects: drug safety -- hemangiomas -- hematology (nonmalignant) -- hematology/oncology -- Kasabach–Merritt phenomenon -- patient safety -- pediatric hematology/oncology -- pharmacology -- pharmacovigilance -- vascular malformations -- vascular tumors; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29364
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Off‐label drug prescribing, frequent in the treatment of vascular anomalies (VA), relies on the quality of the literature reporting drug efficacy and safety. Our objective is to review the level of evidence (LOE) surrounding drug use in VA, which is more prevalent in pediatric care. A list of drugs used in VA was created with a literature review in July 2020. For each drug listed, the article displaying the highest LOE was determined and then compared between efficacy/safety data, routes of administration, pharmacological categories and a subset of VA. The influence of research quality on study results was also explored. The median LOE for the 74 drugs identified poor methodological quality, with a predominance of retrospective studies or case reports. Drug safety is currently inadequately reported. This is alarming as many treatments display significant safety concerns. Also, current literature displays major publication bias that probably leads to overestimation of drug efficacy in VA.